Aldeyra Therapeutics Statistics
Share Statistics
Aldeyra Therapeutics has 59.9M
shares outstanding. The number of shares has increased by 0.5%
in one year.
| Shares Outstanding | 59.9M |
| Shares Change (YoY) | 0.5% |
| Shares Change (QoQ) | 0.27% |
| Owned by Institutions (%) | 62.48% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 69,720 |
| FTD / Avg. Volume | 3.88% |
Short Selling Information
The latest short interest is 4.75M, so 7.94% of the outstanding
shares have been sold short.
| Short Interest | 4.75M |
| Short % of Shares Out | 7.94% |
| Short % of Float | 8.18% |
| Short Ratio (days to cover) | 3.04 |
Valuation Ratios
The PE ratio is -5.31 and the forward
PE ratio is 19.14.
Aldeyra Therapeutics's PEG ratio is
-0.11.
| PE Ratio | -5.31 |
| Forward PE | 19.14 |
| PS Ratio | 0 |
| Forward PS | 0.7 |
| PB Ratio | 4.18 |
| P/FCF Ratio | -6.87 |
| PEG Ratio | -0.11 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Aldeyra Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.48,
with a Debt / Equity ratio of 0.22.
| Current Ratio | 5.48 |
| Quick Ratio | 5.48 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | -0.25 |
| Debt / FCF | -0.35 |
| Interest Coverage | -31.21 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-6,205,716 |
| Employee Count | 9 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -42.54% in the
last 52 weeks. The beta is 0.68, so Aldeyra Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.68 |
| 52-Week Price Change | -42.54% |
| 50-Day Moving Average | 2.86 |
| 200-Day Moving Average | 4.85 |
| Relative Strength Index (RSI) | 47.09 |
| Average Volume (20 Days) | 1,796,768 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -60.12M |
| Net Income | -55.85M |
| EBITDA | -60.12M |
| EBIT | -57.78M |
| Earnings Per Share (EPS) | -0.94 |
Full Income StatementBalance Sheet
The company has 54.53M in cash and 15.3M in
debt, giving a net cash position of 39.22M.
| Cash & Cash Equivalents | 54.53M |
| Total Debt | 15.3M |
| Net Cash | 39.22M |
| Retained Earnings | -450.11M |
| Total Assets | 93.2M |
| Working Capital | 77M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -43.21M
and capital expenditures 0, giving a free cash flow of -43.21M.
| Operating Cash Flow | -43.21M |
| Capital Expenditures | n/a |
| Free Cash Flow | -43.21M |
| FCF Per Share | -0.73 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
